ClinicalTrials.gg
CompletedNCT01780506Updated Nov 19, 2018Results posted

Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

A Phase 3 interventional study of E/C/F/TAF and E/C/F/TDF in HIV and HIV Infections, sponsored by Gilead Sciences. Completed at 117 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-19.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
872
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing elvitegravir in HIV Infections — none open to participants now, none under way, none of them phase 3. elvitegravir · HIV Infections.

Enrollment
2nd of 11
872 · median 252
Started
2012
the only one that year
Phase 3
7 of 11
none open now
Registered
4th of 11
by date
Lead sponsor
11 of 11
Gilead Sciences

Among the 11 studies testing elvitegravir in HIV Infections, this one is the 2nd largest by enrollment, is the only one that started in 2012, is one of 7 in phase 3, and was the 4th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 11 studies testing elvitegravir in HIV Infections is open now. The open studies under HIV Infections, anywhere →

About elvitegravir

elvitegravir: first FDA approval 2012 (STRIBILD), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing elvitegravir in HIV Infections as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) FDC in HIV-1 positive, antiretroviral treatment-naive adults.

03

Conditions studied

  • HIV
  • HIV Infections

Browse trials for

Keywords

  • HIV
  • Treatment Naive
  • HIV 1 Infected
  • Female
  • Women
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Ability to understand and sign a written form, which must be obtained prior to initiation of study procedures
  • Plasma -1 RNA levels ≥ 1,000 copies/mL at screening
  • No prior use of any approved or antiretroviral drug for any length of time, except the use for pre-exposure prophylaxis (PREP) or post-exposure prophylaxis (PEP), up to 6 months prior to screening
  • Screening genotype report must show sensitivity to elvitegravir, emtricitabine, tenofovir disoproxil fumarate (tenofovir DF)
  • Normal (ECG)
  • Estimated (eGFR) ≥ 50 mL/min according to the formula for creatinine clearance
  • Hepatic transaminases ( and ALT) ≤ 5 × (ULN)
  • Total ≤ 1.5 mg/dL, or normal direct bilirubin
  • Adequate hematologic function
  • Serum amylase ≤ 5 × ULN
  • Males and females of must agree to utilize highly effective methods or be non-heterosexually active or practice sexual abstinence from screening throughout the duration of study treatment and for 30 days following the last dose of study drug
  • Females who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least three months prior to study dosing
  • Females who have stopped menstruating for ≥ 12 months but do not have documentation of ovarian hormonal failure must have a serum follicle stimulating hormone (FSH) level at screening within the range based on the Central Laboratory reference range

Key Exclusion Criteria:

  • A new acquired immunodeficiency syndrome (AIDS) defining condition diagnosed within the 30 days prior to screening
  • surface antigen (HBsAg) positive
  • antibody positive
  • Individuals experiencing decompensated cirrhosis
  • Females who are breastfeeding
  • Positive serum pregnancy test
  • Have an implanted defibrillator or pacemaker
  • Current alcohol or substance use judged by the Investigator to potentially interfere with study compliance
  • History of within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, noninvasive cutaneous squamous carcinoma
  • Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to baseline
  • Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the individual unsuitable for the study or unable to comply with dosing requirements
  • Participation in any other clinical trial (including observational trials) without prior approval
  • Individuals receiving ongoing therapy with drugs not to be used with elvitegravir, cobicistat, emtricitabine, tenofovir DF, and TAF or individuals with any known allergies to the of E/C/F/TDF or E/C/F/TAF single-tablet regimen tablets

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
872 participants (actual)

Study arms

  • Experimental
    E/C/F/TAF (Double-Blind Phase)

    E/C/F/TAF plus E/C/F/TDF placebo for 144 weeks

    Drug: E/C/F/TAF · Drug: E/C/F/TDF Placebo

  • Active comparator
    E/C/F/TDF (Double-Blind Phase)

    E/C/F/TDF plus E/C/F/TAF placebo for 144 weeks

    Drug: E/C/F/TDF · Drug: E/C/F/TAF Placebo

  • Experimental
    Open-Label Extension Phase

    After study unblinding, participants who complete 144 weeks of the study had the option to receive open-label E/C/F/TAF until commercially available, or until Gilead Sciences terminated the study in that country.

    Drug: E/C/F/TAF

Interventions

  • DrugE/C/F/TAF

    Drug pages: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide

    150/150/200/10 mg FDC tablet administered orally once daily

    Also known as: Genvoya®

  • DrugE/C/F/TDF

    150/150/200/300 mg FDC tablet administered orally once daily

    Also known as: Stribild®

  • DrugE/C/F/TDF Placebo

    Tablet administered orally once daily

  • DrugE/C/F/TAF Placebo

    Tablet administered orally once daily

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

Secondary outcomes

  1. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Weeks 96 and 144

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Weeks 96 and 144 were analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Weeks 96 and 144

  2. Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Weeks 48, 96, and 144

    The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Weeks 48, 96, and 144 were analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Weeks 48, 96. and 144

  3. Change From Baseline in CD4+ Cell Count at Week 48

    Time frame: Baseline; Week 48

  4. Change From Baseline in CD4+ Cell Count at Week 96

    Time frame: Baseline; Week 96

  5. Change From Baseline in CD4+ Cell Count at Week 144

    Time frame: Baseline; Week 144

  6. Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

    Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan.

    Time frame: Baseline; Week 48

  7. Percent Change From Baseline in Hip BMD at Week 96

    Hip BMD was assessed by DXA scan.

    Time frame: Baseline; Week 96

  8. Percent Change From Baseline in Hip BMD at Week 144

    Hip BMD was assessed by DXA scan.

    Time frame: Baseline; Week 144

  9. Percent Change From Baseline in Spine BMD at Week 48

    Spine BMD was assessed by DXA scan.

    Time frame: Baseline; Week 48

  10. Percent Change From Baseline in Spine BMD at Week 96

    Spine BMD was assessed by DXA scan.

    Time frame: Baseline; Week 96

  11. Percent Change From Baseline in Spine BMD at Week 144

    Spine BMD was assessed by DXA scan.

    Time frame: Baseline; Week 144

  12. Change From Baseline in Serum Creatinine at Week 48

    Time frame: Baseline; Week 48

  13. Change From Baseline in Serum Creatinine at Week 96

    Time frame: Baseline; Week 96

  14. Change From Baseline in Serum Creatinine at Week 144

    Time frame: Baseline; Week 144

  15. Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 48

    Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant.

    Time frame: Up to 48 weeks

  16. Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 96

    Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant.

    Time frame: Up to 96 weeks

  17. Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 144

    Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant.

    Time frame: Up to 144 weeks

  18. Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48

    Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury.

    Time frame: Baseline; Week 48

  19. Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96

    Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury.

    Time frame: Baseline; Week 96

  20. Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 144

    Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury.

    Time frame: Baseline; Week 144

  21. Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 48

    Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury.

    Time frame: Baseline; Week 48

  22. Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 96

    Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury.

    Time frame: Baseline; Week 96

  23. Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 144

    Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury.

    Time frame: Baseline; Week 144

07

Results

Posted Jan 8, 2016

Participant flow

Participants were enrolled at study sites in North America, Europe, and Asia. The first participant was screened on 26 December 2012. The last study visit occurred on 06 September 2017.

Double-Blind Phase
Participant flow — Double-Blind Phase
MilestoneE/C/F/TAFE/C/F/TDF
Started438434
Completed368356
Not completed7078
Withdrew: Randomized but not treated32
Withdrew: Adverse event414
Withdrew: Death12
Withdrew: Pregnancy21
Withdrew: Lack of efficacy11
Withdrew: Investigator's discretion52
Withdrew: Non-compliance with study drug43
Withdrew: Protocol violation43
Withdrew: Withdrew consent2324
Withdrew: Lost to follow-up2326
Open-Label Extension Phase
Participant flow — Open-Label Extension Phase
MilestoneE/C/F/TAFE/C/F/TDF
Started9095
Completed9094
Not completed01
Withdrew: Enrolled but not treated01

Outcome measures

PrimaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48
percentage of participantsE/C/F/TAFE/C/F/TDF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 4893.192.8
Statistical analysis
  • E/C/F/TAF vs E/C/F/TDF · Cochran-Mantel-Haenszel · p = 0.78 (P-value was from the Cochran-Mantel-Haenszel (CMH) test stratified by baseline HIV-1 RNA (≤ 100,000 or \> 100,000 copies/mL) and region (US vs ex-US).) · Difference in percentages: 0.5 · 95.002% CI -3.0 to 4.0The difference in percentages and its 95.002% confidence interval (CI) were calculated based on the Mantel-Haenszel (MH) proportions adjusted by baseline HIV-1 RNA and region stratum.
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Weeks 96 and 144

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Weeks 96 and 144 were analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Weeks 96 and 144
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Weeks 96 and 144
percentage of participantsE/C/F/TAFE/C/F/TDF
Week 9689.288.2
Week 14486.983.1
SecondaryPercentage of Participants With HIV-1 RNA < 20 Copies/mL at Weeks 48, 96, and 144

The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Weeks 48, 96, and 144 were analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Weeks 48, 96. and 144
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Weeks 48, 96, and 144
percentage of participantsE/C/F/TAFE/C/F/TDF
Week 4886.487.3
Week 9684.483.6
Week 14484.680.1
SecondaryChange From Baseline in CD4+ Cell Count at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · cells/µL
Change From Baseline in CD4+ Cell Count at Week 48
cells/µLE/C/F/TAFE/C/F/TDF
Change From Baseline in CD4+ Cell Count at Week 48235 ± 183.1221 ± 178.9
SecondaryChange From Baseline in CD4+ Cell Count at Week 96
Time frame:
Baseline; Week 96
Reported as:
Mean · cells/µL
Change From Baseline in CD4+ Cell Count at Week 96
cells/µLE/C/F/TAFE/C/F/TDF
Change From Baseline in CD4+ Cell Count at Week 96285 ± 203.0271 ± 208.1
SecondaryChange From Baseline in CD4+ Cell Count at Week 144
Time frame:
Baseline; Week 144
Reported as:
Mean · cells/µL
Change From Baseline in CD4+ Cell Count at Week 144
cells/µLE/C/F/TAFE/C/F/TDF
Change From Baseline in CD4+ Cell Count at Week 144323 ± 213.1310 ± 207.2
SecondaryPercent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan.

Time frame:
Baseline; Week 48
Reported as:
Mean · percent change
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48
percent changeE/C/F/TAFE/C/F/TDF
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48-0.865 ± 3.2532-3.200 ± 3.1759
SecondaryPercent Change From Baseline in Hip BMD at Week 96

Hip BMD was assessed by DXA scan.

Time frame:
Baseline; Week 96
Reported as:
Mean · percent change
Percent Change From Baseline in Hip BMD at Week 96
percent changeE/C/F/TAFE/C/F/TDF
Percent Change From Baseline in Hip BMD at Week 96-0.951 ± 3.8633-3.515 ± 3.9451
SecondaryPercent Change From Baseline in Hip BMD at Week 144

Hip BMD was assessed by DXA scan.

Time frame:
Baseline; Week 144
Reported as:
Mean · percent change
Percent Change From Baseline in Hip BMD at Week 144
percent changeE/C/F/TAFE/C/F/TDF
Percent Change From Baseline in Hip BMD at Week 144-0.826 ± 4.6786-3.475 ± 4.1551
SecondaryPercent Change From Baseline in Spine BMD at Week 48

Spine BMD was assessed by DXA scan.

Time frame:
Baseline; Week 48
Reported as:
Mean · percent change
Percent Change From Baseline in Spine BMD at Week 48
percent changeE/C/F/TAFE/C/F/TDF
Percent Change From Baseline in Spine BMD at Week 48-1.337 ± 3.0715-2.956 ± 3.3524
SecondaryPercent Change From Baseline in Spine BMD at Week 96

Spine BMD was assessed by DXA scan.

Time frame:
Baseline; Week 96
Reported as:
Mean · percent change
Percent Change From Baseline in Spine BMD at Week 96
percent changeE/C/F/TAFE/C/F/TDF
Percent Change From Baseline in Spine BMD at Week 96-0.907 ± 4.0039-3.053 ± 3.9539
SecondaryPercent Change From Baseline in Spine BMD at Week 144

Spine BMD was assessed by DXA scan.

Time frame:
Baseline; Week 144
Reported as:
Mean · percent change
Percent Change From Baseline in Spine BMD at Week 144
percent changeE/C/F/TAFE/C/F/TDF
Percent Change From Baseline in Spine BMD at Week 144-0.809 ± 4.5041-3.023 ± 4.3122
SecondaryChange From Baseline in Serum Creatinine at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · mg/dL
Change From Baseline in Serum Creatinine at Week 48
mg/dLE/C/F/TAFE/C/F/TDF
Change From Baseline in Serum Creatinine at Week 480.08 ± 0.1100.11 ± 0.116
SecondaryChange From Baseline in Serum Creatinine at Week 96
Time frame:
Baseline; Week 96
Reported as:
Mean · mg/dL
Change From Baseline in Serum Creatinine at Week 96
mg/dLE/C/F/TAFE/C/F/TDF
Change From Baseline in Serum Creatinine at Week 960.05 ± 0.1090.07 ± 0.132
SecondaryChange From Baseline in Serum Creatinine at Week 144
Time frame:
Baseline; Week 144
Reported as:
Mean · mg/dL
Change From Baseline in Serum Creatinine at Week 144
mg/dLE/C/F/TAFE/C/F/TDF
Change From Baseline in Serum Creatinine at Week 1440.04 ± 0.1150.08 ± 0.133
SecondaryPercentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 48

Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant.

Time frame:
Up to 48 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 48
percentage of participantsE/C/F/TAFE/C/F/TDF
Grade 125.832.3
Grade 24.64.9
Grade 300.2
SecondaryPercentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 96

Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant.

Time frame:
Up to 96 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 96
percentage of participantsE/C/F/TAFE/C/F/TDF
Grade 128.833.9
Grade 25.15.8
Grade 30.20.2
SecondaryPercentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 144

Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant.

Time frame:
Up to 144 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 144
percentage of participantsE/C/F/TAFE/C/F/TDF
Grade 131.337.1
Grade 26.07.0
Grade 30.20.2
SecondaryPercent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury.

Time frame:
Baseline; Week 48
Reported as:
Median · percent change
Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48
percent changeE/C/F/TAFE/C/F/TDF
Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 486.9 (-23.3 to 42.1)51.2 (3.3 to 127.1)
SecondaryPercent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury.

Time frame:
Baseline; Week 96
Reported as:
Median · percent change
Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96
percent changeE/C/F/TAFE/C/F/TDF
Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 9611.3 (-20.3 to 61.5)75.0 (9.9 to 182.6)
SecondaryPercent Change From Baseline in Urine RBP to Creatinine Ratio at Week 144

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury.

Time frame:
Baseline; Week 144
Reported as:
Median · percent change
Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 144
percent changeE/C/F/TAFE/C/F/TDF
Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 14437.4 (-6.0 to 87.3)106.9 (38.0 to 254.9)
SecondaryPercent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 48

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury.

Time frame:
Baseline; Week 48
Reported as:
Median · percent change
Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 48
percent changeE/C/F/TAFE/C/F/TDF
Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 48-32.8 (-58.7 to 1.3)18.0 (-28.8 to 171.6)
SecondaryPercent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 96

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury.

Time frame:
Baseline; Week 96
Reported as:
Median · percent change
Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 96
percent changeE/C/F/TAFE/C/F/TDF
Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 96-33.5 (-60.0 to 2.0)32.5 (-27.8 to 205.6)
SecondaryPercent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 144

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury.

Time frame:
Baseline; Week 144
Reported as:
Median · percent change
Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 144
percent changeE/C/F/TAFE/C/F/TDF
Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 144-24.6 (-57.5 to 13.3)60.4 (-10.4 to 318.8)

Adverse events

Collected over Double-Blind Phase: Up to a maximum of 194.1 weeks plus 30 days; Open-Label Phase: Up to a maximum of 48.3 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-Blind: E/C/F/TAF—73/435 (16.8%)380/435 (87.4%)
Double-Blind: E/C/F/TDF—65/432 (15%)375/432 (86.8%)
Open-Label: E/C/F/TAF to E/C/F/TAF—0/90 (0%)16/90 (17.8%)
Open-Label: E/C/F/TDF to E/C/F/TAF—1/94 (1.1%)14/94 (14.9%)
Most frequent serious events
Showing 10 of 147
Most frequent serious events
EventDouble-Blind: E/C/F/TAFDouble-Blind: E/C/F/TDFOpen-Label: E/C/F/TAF to E/C/F/TAFOpen-Label: E/C/F/TDF to E/C/F/TAF
AppendicitisInfections and infestations8/4353/4320/900/94
InfluenzaInfections and infestations0/4353/4320/901/94
Suicidal ideationPsychiatric disorders4/4352/4320/900/94
CellulitisInfections and infestations0/4353/4320/900/94
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/4353/4320/900/94
Meningitis viralInfections and infestations3/4350/4320/900/94
Rectal haemorrhageGastrointestinal disorders0/4352/4320/900/94
Suicide attemptPsychiatric disorders1/4352/4320/900/94
Acute myocardial infarctionCardiac disorders2/4351/4320/900/94
Abdominal painGastrointestinal disorders2/4350/4320/900/94
Most frequent other events
Showing 10 of 36
Most frequent other events
EventDouble-Blind: E/C/F/TAFDouble-Blind: E/C/F/TDFOpen-Label: E/C/F/TAF to E/C/F/TAFOpen-Label: E/C/F/TDF to E/C/F/TAF
DiarrhoeaGastrointestinal disorders112/435105/4321/901/94
Upper respiratory tract infectionInfections and infestations92/43595/4323/902/94
NauseaGastrointestinal disorders73/43584/4322/900/94
Viral upper respiratory tract infectionInfections and infestations69/43564/4322/901/94
HeadacheNervous system disorders69/43563/4320/900/94
Back painMusculoskeletal and connective tissue disorders50/43561/4320/900/94
CoughRespiratory, thoracic and mediastinal disorders58/43556/4324/901/94
OsteopeniaMusculoskeletal and connective tissue disorders41/43557/4320/900/94
SyphilisInfections and infestations55/43556/4324/902/94
FatigueGeneral disorders49/43547/4320/900/94

Baseline characteristics

Safety Analysis Set: participants who were randomized and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)E/C/F/TAFE/C/F/TDFTotal
Mean35 ± 10.036 ± 10.535 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)E/C/F/TAFE/C/F/TDFTotal
Female7156127
Male364376740
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)E/C/F/TAFE/C/F/TDFTotal
Hispanic or Latino6070130
Not Hispanic or Latino375362737
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)E/C/F/TAFE/C/F/TDFTotal
American Indian or Alaska Native459
Asian7677153
Black9481175
Native Hawaiian or Pacific Islander134
White250255505
Other101121
Region of Enrollment
Region of Enrollment(Participants)E/C/F/TAFE/C/F/TDFTotal
United States252250502
Japan4610
United Kingdom156
Thailand6358121
Switzerland61218
Spain424284
Canada232346
Austria15823
Belgium7714
Italy369
Australia191534
HIV-1 RNA (log10 copies/mL)
HIV-1 RNA (log10 copies/mL)(log10 copies/mL)E/C/F/TAFE/C/F/TDFTotal
Mean4.55 ± 0.6824.55 ± 0.6744.55 ± 0.678
HIV-1 RNA Category
HIV-1 RNA Category(Participants)E/C/F/TAFE/C/F/TDFTotal
≤ 100,000 copies/mL331336667
> 100,000 to ≤ 400,000 copies/mL7972151
> 400,000 copies/mL252449
CD4 Cell Count
CD4 Cell Count(cells/µL)E/C/F/TAFE/C/F/TDFTotal
Mean437 ± 223.7426 ± 212.3432 ± 218.0

2 further baseline measures are reported on the registry.

08

Study locations

117 sites
  • The University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Spectrum Medical Group
    Phoenix, Arizona 85012, United States
  • Kaiser Permanente Los Angeles
    Los Angeles, California 90027, United States
  • University of California, Los Angeles
    Los Angeles, California 90035, United States
  • Peter J. Ruane, MD, Inc.
    Los Angeles, California 90036, United States
  • Anthony Mills MD Inc
    Los Angeles, California 90069, United States
  • East Bay AIDS Center
    Oakland, California 94609, United States
  • Kaiser Permanente - Sacramento
    Sacramento, California 95825, United States
  • La Playa Medical Group and Clinical Research
    San Diego, California 92103, United States
  • University of California, San Diego
    San Diego, California 92103, United States
  • Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Torrance, California 90502, United States
  • Apex Research, LLC
    Denver, Colorado 80209, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06510, United States
  • Dupont Circle Physicians Group, P.C.
    Washington, District of Columbia 20009, United States
  • Whitman Walker Clinic
    Washington, District of Columbia 20009, United States
  • Capital Medical Associates, P.C.
    Washington, District of Columbia 20036, United States
  • Gary Richmond, MD, PA, Inc.
    Fort Lauderdale, Florida 33316, United States
  • Midway Immunology & Research Center, LLC
    Fort Pierce, Florida 34982, United States
  • AIDS Healthcare Foundation
    Miami Beach, Florida 33139, United States
  • The Kinder Medical Group
    Miami, Florida 33133, United States
  • Orlando Immunology Center
    Orlando, Florida 32803, United States
  • IDOCF/ValuHealthMD, LLC
    Orlando, Florida 32806, United States
  • Infectious Diseases Associates
    Pensacola, Florida 32504, United States
  • The University of South Florida
    Tampa, Florida 33602, United States
  • Infectious Disease Research Institute Inc.
    Tampa, Florida 33614, United States
  • St. Joseph's Comprenhensive Research Inisitute
    Tampa, Florida 33614, United States
  • AIDS Research and Treatment Center of the Treasure Coast
    Vero Beach, Florida 32960, United States
  • AIDS Research Consortium of Atlanta
    Atlanta, Georgia 30308, United States
  • Emory University
    Atlanta, Georgia 30308, United States
  • Atlanta ID Group, PC
    Atlanta, Georgia 30309, United States
  • Infectious Disease Specialist of Atlanta
    Decatur, Georgia 30033, United States
  • Mercer University School of Medicine
    Macon, Georgia 31201, United States
  • University of Hawaii - Hawaii Center for AIDS
    Honolulu, Hawaii 96816, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Ruth M. Rothstein CORE Center
    Chicago, Illinois 60612, United States
  • Howard Brown Health Center
    Chicago, Illinois 60613, United States
  • Institute of Human Virology, University of Maryland
    Baltimore, Maryland 21201, United States
  • Community Research Initative
    Boston, Massachusetts 02111, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
  • Metrowest Medical Center
    Framingham, Massachusetts 01702, United States
  • Baystate Infectious Diseases Clinical Research
    Springfield, Massachusetts 01199, United States
  • Be Well Medical Center
    Berkley, Michigan 48072, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Hennepin County Medical Center
    Minneapolis, Minnesota 55415, United States
  • Central West Clinical Research, Inc.
    Saint Louis, Missouri 63108, United States
  • Southampton Healthcare, Inc.
    Saint Louis, Missouri 63139, United States
  • ID Care
    Hillsborough, New Jersey 08844, United States
  • Saint Michael's Medical Center
    Newark, New Jersey 07102, United States
  • Southwest C.A.R.E. Center
    Santa Fe, New Mexico 87505, United States
  • Albany Medical College
    Albany, New York 12208, United States
  • Upstate Infectious Diseases Associates
    Albany, New York 12208, United States
  • Jacobi Medical Center
    Bronx, New York 10461, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • New York Hospital Queens
    Flushing, New York 11355, United States
  • North Shore University Hospital - Division of Infectious Diseases
    Manhasset, New York 11030, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27514, United States
  • Infectious Disease Consultants, PA
    Charlotte, North Carolina 28209, United States
  • Duke University
    Durham, North Carolina 22710, United States
  • Rosedale Infectious Diseases
    Huntersville, North Carolina 28078, United States
  • Summa Health Care Center
    Akron, Ohio 44304, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • The Miriam Hospital
    Providence, Rhode Island 02906, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • University of South Carolina School of Medicine
    Columbia, South Carolina 29203, United States
  • Central Texas Clinical Research
    Austin, Texas 78705, United States
  • St. Hope Foundation, Inc.
    Bellaire, Texas 77401, United States
  • Trinity Health and Wellness Center/AIDS Arms, Inc.
    Dallas, Texas 75208, United States
  • North Texas Infectious Diseases Consultants
    Dallas, Texas 75246, United States
  • Tarrant County Infectious Disease Associates
    Fort Worth, Texas 76104, United States
  • Garcias' Family Health Group
    Harlingen, Texas 78550, United States
  • Therapeutic Concepts, PA
    Houston, Texas 77004, United States
  • Gordon E. Crofoot, MD, PA
    Houston, Texas 77098, United States
  • DCOL Center for Clinical Research
    Longview, Texas 75605, United States
  • Clinical Alliance for Research & Education - Infectious Diseases, LLC (CARE-ID)
    Annandale, Virginia 22003, United States
  • Peter Shalit, MD
    Seattle, Washington 98104, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Holdsworth House Medical Practice
    Darlinghurst, New South Wales 2010, Australia
  • Taylor Square Private Clinic
    Darlington, New South Wales 2010, Australia
  • East Sydney Doctors
    Sydney, New South Wales 2010 NSW, Australia
  • Albion Street Centre
    Sydney, New South Wales 2010, Australia
  • Melbourne Sexual Health Clinic
    Carlton, Victoria 3053, Australia
  • DIAID, Department of Dermatology, Medical University Vienna
    Vienna, 1090, Austria
  • Otto-Wagner-Spital, Sozialmedizinisches Zentrum Baumgartner Hoehe
    Wien, 1140, Austria
  • Hôpital Erasme-ULB
    Anderlecht, Brussels 1070, Belgium
  • CHU Saint-Pierre University Hospital
    Brussels, 1000, Belgium
  • Spectrum Health
    Vancouver, British Columbia V6Z 2T1, Canada
  • Health Sciences Centre Winnipeg
    Winnipeg, Manitoba R3A 1R9, Canada
  • The Ottawa Hospital
    Ottawa, Ontario K1H 8L6, Canada
  • Maple Leaf Research
    Toronto, Ontario M5G 1K2, Canada
  • Clinique Medicale Du Quartier Latin
    Montreal, Quebec H2L 5B1, Canada
  • Clinique medicale l'Actuel
    Montreal, Quebec H2L 5B1, Canada
  • Clinique OPUS
    Montreal, Quebec H3A 1T1, Canada
  • Sunnybrook Health Science Center
    Toronto, M4N 3M5, Canada
  • Ospedale San Raffaele
    Milano, 20127, Italy
  • National Center for Global Health and Medicine AIDS Clinical Center
    Shinjuku-ku, Tokyo, 162-8655, Japan
  • HOPE Clinical Research
    San Juan, 00909, Puerto Rico
  • Hospital Germans Trias i Pujol
    Badalona, 08916, Spain
  • Hospital del Mar
    Barcelona, 08003, Spain

Showing the first 100 of 117 sites across 12 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczer D, Molina JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custodio JM, Plummer A, Zhong L, Cao H, Martin H, Callebaut C, Cheng AK, Fordyce MW, McCallister S; GS-US-292-0104/0111 Study Team. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015 Jun 27;385(9987):2606-15. doi: 10.1016/S0140-6736(15)60616-X. Epub 2015 Apr 15. Erratum In: Lancet. 2016 Apr 30;387(10030):1816. doi: 10.1016/S0140-6736(16)30252-5. PubMed 25890673 ↗
  • Arribas JR, Thompson M, Sax PE, Haas B, McDonald C, Wohl DA, DeJesus E, Clarke AE, Guo S, Wang H, Callebaut C, Plummer A, Cheng A, Das M, McCallister S. Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results. J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):211-218. doi: 10.1097/QAI.0000000000001350. PubMed 28282300 ↗
  • Margot N, Cox S, Das M, McCallister S, Miller MD, Callebaut C. Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate. Antivir Ther. 2017;22(5):443-446. doi: 10.3851/IMP3125. Epub 2017 Jan 11. PubMed 28076335 ↗
  • Margot NA, Kitrinos KM, Fordyce M, McCallister S, Miller MD, Callebaut C. Rare emergence of drug resistance in HIV-1 treatment-naive patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. HIV Clin Trials. 2016 Mar;17(2):78-87. doi: 10.1080/15284336.2016.1142731. PubMed 26892863 ↗
  • Funderburg NT, McComsey GA, Kulkarni M, Bannerman T, Mantini J, Thornton B, Liu HC, Zhang Y, Song Q, Fang L, Dinoso J, Cheng A, McCallister S, Fordyce MW, Das M. Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide. EBioMedicine. 2016 Nov;13:321-327. doi: 10.1016/j.ebiom.2016.10.009. Epub 2016 Oct 11. PubMed 27742226 ↗
  • Wohl D, Oka S, Clumeck N, Clarke A, Brinson C, Stephens J, Tashima K, Arribas JR, Rashbaum B, Cheret A, Brunetta J, Mussini C, Tebas P, Sax PE, Cheng A, Zhong L, Callebaut C, Das M, Fordyce M; GS-US-2,92-01040111 and Study Team. Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results. J Acquir Immune Defic Syndr. 2016 May 1;72(1):58-64. doi: 10.1097/QAI.0000000000000940. PubMed 26829661 ↗
  • Custodio JM, Garner W, Callebaut C, Fordyce M, Plummer A, Zhong L, et al. The Pharmacokinetics of Tenofovir and Tenofovir Diphosphate Following Administration of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate [Oral Abstract #6]. The 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy. Washington DC, USA, May 26-28, 2015.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2012 to primary completion in Aug 2014, 20 months.

Results were first posted in Jan 2016, 1 year 4 months after primary completion. A results delay was requested in Jun 2014.

Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 20 months is close to that.

Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2013
First posted
Jan 31, 2013
StartActual
Dec 26, 2012
Primary completionActual
Aug 26, 2014
CompletionActual
Sep 6, 2017
Results delay requested
Jun 24, 2014
Results first posted
Jan 8, 2016
Last update
Nov 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01780506
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jan 31, 2013
Start date
Dec 26, 2012
Primary completion
Aug 26, 2014
Completion
Sep 6, 2017
Results posted
Jan 8, 2016
Last update
Nov 19, 2018

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide

Start the discussion